Molecular Correlates of Cisplatin-based Chemotherapy Response in Muscle Invasive Bladder Cancer by Integrated Multi-omics Analysis

被引：0

作者：

Taber, A. ^{[1
]}

Christensen, E. ^{[1
]}

Lamy, P. ^{[1
]}

Nordentoft, I ^{[1
]}

Prip, F. F. ^{[1
]}

Lindskrog, C., V ^{[1
]}

Birkenkamp-Demtroder, K. ^{[1
]}

Okholm, T. L. H. ^{[1
]}

Knudsen, M. ^{[1
]}

Pedersen, J. S. ^{[1
]}

Steiniche, T. ^{[1
]}

Agerboek, M. ^{[1
]}

Jensen, J. B. ^{[1
]}

Dyrskjot, L. ^{[1
]}

机构：

[1] Aarhus Univ Hosp, Dept Mol Med MOMA, Aarhus, Denmark

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2020年 / 38卷 / 12期

关键词：

D O I：

10.1016/j.urolonc.2020.10.031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：899 / 899

页数：1

共 50 条

[31] Integrated multi-omics analysis identified cisplatin resistant cancer cells rely on methionine metabolism in bladder cancer microenvironment
Yang, C.
Zhou, Q. Z.
Ou, Y. O.
Wu, S. W.
Jiang, H. J.
EUROPEAN UROLOGY, 2023, 83
[32] Neutrophil extracellular trap as a predictive marker to cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer
Shang, Bing-Qing
Gu, Zhaoru
Qu, Wang
Xie, Rui-Yang
Wu, Jie
Zhou, Ai-Ping
Shou, Jianzhong
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment
Ecke, Thorsten H.
Voss, Paula Carolin
Schlomm, Thorsten
Rabien, Anja
Friedersdorff, Frank
Barski, Dimitri
Otto, Thomas
Waldner, Michael
Veltrup, Elke
Linden, Friederike
Hake, Roland
Eidt, Sebastian
Roggisch, Jenny
Heidenreich, Axel
Rieger, Constantin
Kastner, Lucas
Hallmann, Steffen
Koch, Stefan
Wirtz, Ralph M.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
[34] Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer
Ecke, Thorsten H.
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION, 2015, 867 : 293 - 316
[35] Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study
Yu, Evan Yi-Wen
Zhang, Hao
Fu, Yuanqing
Chen, Ya-Ting
Tang, Qiu-Yi
Liu, Yu-Xiang
Zhang, Yan-Xi
Wang, Shi-Zhi
Wesselius, Anke
Li, Wen-Chao
Zeegers, Maurice P.
Xu, Bin
CURRENT ONCOLOGY, 2022, 29 (08) : 5442 - 5456
[36] PREDICTORS OF RESPONSE FOLLOWING NEOADJUVANT CISPLATIN BASED CHEMOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL BLADDER CANCER USING MOLECULAR PROFILE
Elkarta, Ahmed
Elhefnawy, Ahmed
Abol-Enein, Hassan
Shokeir, Ahmed
JOURNAL OF UROLOGY, 2022, 207 (05): : E974 - E974
[37] Retrospective Analysis of Clinical Outcomes With Neoadjuvant Cisplatin-Based Regimens for Muscle-Invasive Bladder Cancer
Pal, Sumanta K.
Ruel, Nora H.
Wilson, Timothy G.
Yuh, Bertram E.
CLINICAL GENITOURINARY CANCER, 2012, 10 (04) : 246 - 250
[38] Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer
Khaki, Ali Raza
Shan, Yong
Nelson, Richard E.
Kaul, Sapna
Gore, John L.
Grivas, Petros
Williams, Stephen B.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 732.e9 - 732.e16
[39] Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration.
Funt, Samuel Aaron
Solovyov, Alexander
Faltas, Bishoy Morris
Iyer, Gopa
Boyd, Mariel Elena
Cipolla, Catharine Kline
Regazzi, Ashley Marie
Teo, Min Yuen
Lee, Chung-Han
Al-Ahmadie, Hikmat
Rosenberg, Jonathan E.
Greenbaum, Benjamin
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[40] Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
Schardt, Julian
Roth, Beat
Seiler, Roland
WORLD JOURNAL OF UROLOGY, 2019, 37 (09) : 1759 - 1765

← 1 2 3 4 5 →